Zydus Lifesciences Limited has announced a strategic partnership with Bioeq AG, a Swiss biopharmaceutical company, for the licensing, supply, and commercialization of Bioeq's NUFYMCO®, an interchangeable biosimilar to Lucentis® (Ranibizumab), in the U.S. market. The Biologics License Application (BLA) for NUFYMCO® received approval from the U.S. Food and Drug Administration (USFDA) on December 18, 2025. Under the agreement, Bioeq will handle the development, manufacturing, registration, and supply of the finished product. Zydus will be responsible for the commercialization of NUFYMCO® in the U.S. This collaboration expands Zydus' U.S. biosimilar business, following a recent partnership for a biosimilar of Keytruda®. Dr. Sharvil P. Patel, Managing Director of Zydus Lifesciences Limited, expressed enthusiasm for the collaboration, aiming to leverage combined expertise to accelerate growth and improve patient access to affordable ophthalmology care. Dr. Thiemo Schreiber, Vice President Commercial at Bioeq, highlighted the USFDA approval and expressed confidence in Zydus' U.S. distribution network and sales capabilities. The total addressable market opportunity for biosimilar Ranibizumab in the U.S. is approximately US$210 million as per IQVIA MAT Sep 2025.